This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
10/21/14 9:29AM
Ebola stocks have soared in recent weeks but a closer look at fundamentals may serve as a reality check for investors playing the story.
10/21/14 6:10AM
As a pill, Celgene's GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.
10/20/14 10:56AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/17/14 7:05AM
Given the usual hype surrounding small-cap biotechs, Brainstorm CEO Tony Fiorino is refreshingly candid about the company's chances of developing a stem-cell treatment to counter ALS symptoms.
10/16/14 8:30AM
U.S. patients suffering from idiopathic pulmonary fibrosis finally gain access to Esbriet, approved for use in Europe since early 2011.
10/15/14 4:07PM
It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences GILD take a turn south.
10/14/14 10:53AM
Health care investors can be divided into two camps with respect to Sarepta: Those who believe eteplirsen is effective against DMD and those who don't.
10/13/14 12:29PM
Once launched, Harvoni is expected to quickly supplant Sovaldi as the standard of care for the treatment of hepatitis C patients.
10/10/14 2:15PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/10/14 7:00AM
If confirmed later this year, the $502 price for Cologuard is a big win for Exact Sciences because it means Medicare gave the company everything asked for during reimbursement negotiations.
10/10/14 6:55AM
CEOs of early stage biotech companies like Arrowhead cannot deliver nasty surprises to Wall Street, yet some inexplicable reason, Anzalone totally botched the job.
10/8/14 3:52PM
Tekmira shares surge after Thomas Duncan's death announced.
10/8/14 11:33AM
In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.
10/8/14 10:38AM
If Northwest Bio's cancer vaccines -- DCVax-L and DCVax Direct -- are so promising, hedge funds should be falling over themselves to own the stock, not short it.
10/8/14 7:43AM
For the past three months, small-cap biotech stocks have been underperforming the broader market.
10/7/14 11:39AM
Treatment with an experimental formulation of vitamin B6 known as MDX failed to improve the symptoms of attention-deficit hyperactivity disorder compared to placebo.
10/6/14 10:08AM
Sunesis' experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.
10/6/14 7:00AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/3/14 9:41AM
Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.
10/1/14 10:08AM
Martin is super smart and will be a great asset somewhere, but he is not a CEO. I wish him the best.
9/30/14 5:53PM
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
9/30/14 9:49AM
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
9/30/14 7:20AM
Clovis Oncology shares are higher Monday because AstraZeneca, its direct competitor to develop a new, genetically targeted lung cancer drug, slipped this weekend.
9/29/14 12:17PM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs